REGENXBIO Balance Sheet
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
REGENXBIO financial position
At the end of fiscal 2025, REGENXBIO reported total assets of $453.0 million, down 2.8% from a year earlier against total liabilities of $350.3 million. Shareholders' equity stood at $102.7 million, or 22.7% of assets. The company held $34.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.38, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
REGENXBIO balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 34.47M | 57.53M | 34.52M | 96.95M | 345.21M | 338.43M | 69.51M | 75.56M | 46.66M | 24.84M |
| Short-Term Investments | 195.60M | 177.16M | 240.74M | 267.69M | 112.23M | 137.31M | 226.70M | 244.20M | 114.12M | 64.71M |
| Receivables | 26.38M | 20.47M | 24.79M | 28.08M | 32.44M | 43.00M | 38.15M | — | — | — |
| Total Current Assets | 281.28M | 278.00M | 334.97M | 415.98M | 518.83M | 531.20M | 345.03M | 337.91M | 168.00M | 93.37M |
| Property, Plant & Equipment | 104.86M | 117.59M | 132.10M | 141.69M | 131.55M | 56.47M | 28.97M | 28.70M | 13.98M | 9.32M |
| Long-Term Investments | 10.79M | 10.18M | 38.87M | 200.56M | 391.91M | 46.81M | 103.78M | 150.82M | 15.62M | 69.41M |
| Total Assets | 453.03M | 465.99M | 573.97M | 833.27M | 1.11B | 708.16M | 497.91M | 543.81M | 198.68M | 172.73M |
| Accounts Payable | 21.36M | 22.80M | 22.79M | 27.21M | 11.39M | 10.62M | 6.41M | 4.41M | 4.83M | 1.54M |
| Total Current Liabilities | 118.09M | 103.19M | 130.27M | 130.43M | 130.47M | 81.45M | 33.68M | 22.18M | 14.44M | 9.67M |
| Total Liabilities | 350.30M | 206.34M | 262.23M | 317.07M | 349.61M | 330.41M | 47.71M | 34.97M | 15.65M | 10.99M |
| Shareholders' Equity | 102.73M | 259.65M | 311.74M | 516.20M | 764.30M | 377.75M | 450.20M | 508.85M | 183.03M | 161.74M |
| Retained Earnings | -1.13B | -932.15M | -705.05M | -441.55M | -161.23M | -289.07M | -177.82M | -83.02M | -187.76M | -114.59M |
| Net Cash (Debt) | 230.07M | 234.69M | 275.26M | 364.64M | 457.44M | 475.74M | 296.21M | 319.76M | 160.78M | 89.55M |
| Shares Outstanding | 50.89M | 49.55M | 44.05M | 43.30M | 42.83M | 37.48M | 36.99M | 36.12M | 31.30M | 26.48M |
This table shows 10 annual periods of REGENXBIO's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RGNX's reporting calendar. What is a balance sheet?